secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000123
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials
--------------------------------------------------------------------------------

- Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.
- BP1001-A Phase 1/1b solid tumors advanced to second dose cohort; one patient had 15% tumor reduction after 9 cycles; second/third cohorts expected to complete 2025.
- BP1002 Phase 1/1b relapsed/refractory AML: third dose cohort (60 mg/m2) enrollment closed faster than expected; no dose limiting toxicities.
- New preclinical program: BP1001-A for obesity in Type 2 diabetes; expects to file IND in 2025 after completing preclinical testing.
- Patent portfolio includes 7 US patents, 61 foreign patents, and multiple applications pending worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/0001558370-25-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/bpth-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer